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Abstract 
In the clinical setting, calculating cardiovascular disease (CVD) risk is commonplace but the utility of the 
harmonised equation for metabolic syndrome (MetS) (Alberti et al., 2009) is less well established. The 
aims of this study were to apply this equation to an overweight clinical cohort to identify risk factors for 
being metabolically unhealthy and explore associations with chronic disease. Baseline data were 
analysed from a lifestyle intervention trial of Illawarra residents recruited in 2014/2015. Participants were 
aged 25–54 years with a BMI 25–40 kg/m2. Data included MetS, CVD risk, insulin sensitivity, weight, body 
fat, diet, peripheral artery disease (PAD), physical activity, socio-economic position and psychological 
profile. Backward stepwise regression tested the association of covariates with MetS status and linear or 
logistic regression tested associations between MetS and risk of CVD, coronary heart disease, PAD and 
insulin resistance. 374 participants were included in the analysis with 127 (34.0%) categorised with MetS. 
Covariates significantly and positively associated with MetS were higher BMI (odds 1.26, p < 0.01) and 
older age (odds 1.08, p < 0.01). MetS participants (n = 351) had a 4.50% increase in CVD risk and were 8.1 
and 12.7 times (respectively) more likely to be at risk of CHD and insulin resistance, compared to 
participants without MetS. The utility of the harmonised equation in the clinical setting was confirmed in 
this overweight clinical cohort. Those classified as having MetS were more likely to be older, overweight/
obese individuals and they had a substantially higher risk of developing CVD and insulin resistance than 
those without MetS. 
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Abstract  
In the clinical setting, calculating cardiovascular disease (CVD) risk is commonplace but the utility of 
the harmonised equation for metabolic syndrome (MetS) [1] is less well established. The aims of this 
study were to apply this equation to an overweight clinical cohort to identify risk factors for being 
metabolically unhealthy and explore associations with chronic disease. 
Baseline data were analysed from a lifestyle intervention trial of Illawarra residents recruited in 
2014/2015. Participants were aged 25-54 years with a BMI 25-40kg/m2. Data included MetS, CVD 
risk, insulin sensitivity, weight, body fat, diet, peripheral artery disease (PAD), physical activity, socio-
economic position and psychological profile. Backward stepwise regression tested the association of 
covariates with MetS status and linear or logistic regression tested associations between MetS and 
risk of CVD, coronary heart disease, PAD and insulin resistance. 374 participants were included in the 
analysis with 127 (34.0%) categorised with MetS. Covariates significantly and positively associated 
with MetS were higher BMI (odds 1.26, p<0.01) and older age (odds 1.08, p<0.01). MetS participants 
(n=351) had a 4.50% increase in CVD risk and were 8.1 and 12.7 times (respectively) more likely to 
be at risk of CHD and insulin resistance, compared to participants without MetS.  
The utility of the harmonised equation in the clinical setting was confirmed in this overweight clinical 
cohort. Those classified as having MetS were more likely to be older, overweight/obese individuals 
and they had a substantially higher risk of developing CVD and insulin resistance than those without 
MetS.  
 
 
 
 
Key Words: metabolically unhealthy; metabolic syndrome; cardiovascular disease risk; insulin 
resistance; lifestyle factors; obesity 
 
The study is registered with the ANZ Clinical Trial Registry (ANZCTRN12614000581662). 
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Introduction  
A decline in metabolic health often precedes cardiovascular disease (CVD) and diabetes mellitus, so 
there are benefits in early identification and intervention. Definitions of “metabolically unhealthy” 
vary. Investigators have frequently used either the absence of metabolic syndrome (MetS), high 
insulin sensitivity, or a combination of both to define metabolic health in overweight or obese 
individuals [2, 3]. A global definition of MetS now exists [1] that unifies previously published 
equations with an agreement that central obesity is not an obligatory component. The harmonised 
definition of MetS is defined as having three of the following: elevated waist circumference (country 
specific guidelines), triglycerides ≥ 1.7mmol/L*, systolic blood pressure ≥130 or diastolic ≥85mmHg*, 
glucose ≥ 100mg/dL and reduced HDL cholesterol <1.0 mmol/L (males) or <1.3mmol/L (females) (or 
drug treatment as indicated*) [1]. Recently published studies have also been found to use previous 
MetS equations [2, 4, 5]. While risk calculations of CVD are readily available [6, 7], the identification 
of MetS is not commonly used in practise and could help initiate early intervention for disease 
prevention. 
MetS often occurs in the presence of obesity which is known to cause a decline in life expectancy 
due to its associated metabolic and cardiovascular comorbid disorders. Clinical practice guidelines 
for obesity defer to treatment with diet, physical1 activity and behavioural support [8]. However, 
recent research suggests that not all obese individuals have the same metabolic risk profile [9] and 
this has implications for personalising treatment. In the first instance it may be relevant to 
distinguish individuals at high risk for obesity-related metabolic diseases by identifying the presence 
of MetS. 
In addition to traditional risk factors such as obesity, many other factors have been suggested as 
being associated with MetS, such as chronic stress [10]; socioeconomic position [11]; 
cardiorespiratory fitness [12], peripheral artery disease (PAD) [13], and dietary saturated fatty acids 
[4]. These all have implications for the mode of treatment, particularly in relation to the nature of 
diet, exercise and psychological support. 
                                                          
1. List of abbreviations  
Metabolic Syndrome (MetS), body mass index (BMI), ankle brachial index (ABI), systolic blood pressure (SBP), 
diastolic blood pressure (DBP), international physical activity questionnaire (IPAQ), depression anxiety stress 
scale (DASS-21), cardiovascular disease (CVD), coronary heart disease (CHD). 
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The aims of this study were to apply the harmonised equation for calculation of MetS to a clinical 
cohort and to identify risk factors for being metabolically unhealthy, as well as assess presence of 
MetS and risk of chronic disease. 
Methods 
Study Design and Setting 
This paper reports on a secondary analysis of data from the HealthTrack study, a 12 month healthy 
lifestyle randomised clinical trial. Participants were randomised to receiving either usual care 
(general advice), or individualised dietary advice with exercise prescription and health coaching, with 
or without a healthy food supplement (walnuts). Participants were recruited from the Illawarra 
region of NSW between May 2014 and April 2015. Inclusion criteria for the study were: permanent 
residents of the Illawarra region (NSW, Australia), adults aged 25-54 years, and with a body mass 
index (BMI) in the range 25-40kg/m2. Exclusion criteria were: unable to communicate in English; 
severe medical conditions, impaired ability to participate; suffering from immunodeficiency; 
reported illegal drug use or regular alcohol intake (>50g/day). Ethical approval was granted by the 
University of Wollongong/Illawarra Shoalhaven Local Health District Human Research Ethics 
Committee (Health and Medical) (HE 13/189). Full written consent was obtained prior to study 
commencement. The study is registered with the ANZ Clinical Trial Registry 
(ANZCTRN12614000581662). 
Full details of the protocol and methodology have previously been described [14]. In summary, at 
baseline 377 participants had body weight (kg) and %body fat measured using scales with a bio-
electrical impedance component. Fasting blood lipids (total cholesterol, LDL, HDL, triglycerides) and 
blood glucose were collected and tested through a registered pathology service (Southern IML 
Pathology). Systolic (SBP) and diastolic blood pressure (DBP) was measured using the Omron BP-
203RPEIII VP-1000 device (Omron Health Care, Kyoto, Japan). Arterial stiffness (baPWV) and arterial 
occlusion (ankle brachial index - ABI) data were also collected from this device, giving a direct 
measure of peripheral artery disease. An ABI of <0.90 or >1.40 was classified as indicative of 
peripheral artery disease, ABI between 0.90 and 1.00 was classified as at risk of peripheral artery 
disease, and ABI between 1.01 and 1.39 was classified as healthy. Dietary intake was assessed using 
4 day food records completed by participants, which included one weekend day. Dietary data was 
analysed using FoodWorks software (Version 7, 2012, Xyris Software, Spring Hill, QLD, Australia). 
Food intake data was converted to energy and macronutrient intake using the AUSNUT2007 food 
composition database [15]. Physical activity was assessed using the International Physical Activity 
Questionnaire (IPAQ) short form survey questions [16] and by a scientific grade pedometer (Yamax 
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Digiwalker SW200, Pedometers Australia) worn for 4 consecutive days to confirm an average 
number of steps per day. Psychological profile was assessed using the Physical and Mental Quality 
of Life Assessment (SF-12)[17] and the Depression Anxiety Stress Scale (DASS – 21)[18]. Socio 
economic position was approximated by the use of level of education attained and the average 
household income, which were both self-reported in an on-line population survey completed during 
screening for the randomised controlled trial. These covariates were included in the analysis as they 
are related to the three components of the lifestyle intervention which were implemented in the 
HealthTrack study after the baseline assessment, those being: dietary counselling, exercise advice 
and psychological coaching. 
MetS was calculated using the harmonized definition [1], with waist circumference thresholds set at 
the AHA/NHLBI (ATP III) levels of > 102 cm for males and >88cm for females. Participants were 
categorised as MUO if MetS was present or MHO if no MetS was present. Framingham CVD and 
coronary heart disease (CHD) risk were calculated based on the published CVD equations [6] and 
CHD score sheets [7]. A risk percentage of less than 10% was categorised as ‘low risk’, and 10% or 
more were categorised as ‘moderate to high risk’ (< 1% had a high risk of CVD and CHD, therefore 
moderate and high risk categories were combined). Similarly, for ABI the peripheral artery disease 
category (<0.90) was combined with the at risk category (0.91 – 1.00) for analysis. Insulin resistance 
was defined as participants prescribed hypoglycaemic agents or a glycated haemoglobin (HbA1c) 
level > 6%.  
Statistical Analysis 
The statistical package used for analysis was IBM SPSS Statistics (version 21.0, IBM Corp, Chicago IL, 
2012). Analyses included baseline data from all participants recruited into the HealthTrack study. 
The cross-sectional associations between physiological and lifestyle covariates and those classified as 
having MetS were analysed using backward stepwise logistic regression. Covariates included 
demographic (age, BMI, gender, % body fat); psychological (DASS-21, SF12 mental scale); physical 
activity (IPAQ, steps/day); dietary (total kilojoules, total fat, monounsaturated fatty acid (MUFA), 
polyunsaturated fatty acid (PUFA) and saturated fat); and social (education level, household 
income). Predictors which achieved a p value <0.2 in univariate analysis were assessed for inclusion 
in the multivariate model. The final model was checked using forward elimination (data not shown). 
Linear regression was used to examine associations between incidence of MetS and CVD risk, whilst 
logistic regression was used to test associations between MetS and CHD risk, peripheral artery 
disease and insulin resistance.  
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Results  
Of the 377 participants randomised, data required for calculation of MetS was available for 374, and 
127 participants (34.0%) were classified with MetS (Table1). Multivariate analysis demonstrated that 
having a higher BMI (odds 1.26, p<0.01) and older age (odds 1.08, p<0.01) were significantly and 
positively associated with having MetS (Table 2). None of the other psychological, physical, dietary 
or social factors had a significant association with MetS classification.  
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Table 1: Baseline characteristics of Illawarra (NSW, Australia) participants 
Baseline characteristic MetS (n=127) No Mets (n=247) 
DEMOGRAPHIC 
Males/females (%) 
Age (years) 
Body mass index (kg/m2) 
Body Fat (%) (n=371) 
METABOLIC 
Systolic blood pressure (mmHg) 
HDL (mmol/L) 
Total cholesterol (mmol/L) 
Triglycerides (mmol/L) 
Glucose (mmol/L) 
Smoker/non-smoker (%) (n=373) 
Waist circumference (cm) 
PSYCHOLOGICAL 
DASS depression (%high*) 
DASS anxiety (%high*) 
DASS stress (%high*) 
DASS total 
SF 12 mental (n=370) 
PHYSICAL ACTIVITY 
IPAQ (METS) (n=368) 
Steps/day (n=294) 
DIETARY 
Total energy (kJ) (n=336) 
Energy from fat (%)(n=336) 
MUFA (% of fat) (n=336) 
PUFA (% of fat) (n=336) 
Saturated fat (% of fat) (n=336) 
SOCIAL 
University/post grad degree (%) 
Household income < $80,000 (%) 
Household income $80-159,999 (%) 
Household income > $160,000 (%) 
Income not recorded (%) 
PHARMACOLOGICAL 
Antihypertensive (%) 
Hypolipidaemic (%) 
Antidepressant/Antianxiety (%) 
 
33/67 
45.8 ± 6.6 
35.1 ± 3.9 
42.4 ± 6.6 
 
135.0 ± 14.9 
1.2 ± 0.3 
5.4 ± 1.1 
1.8 ± 0.9 
6.0 ± 1.7 
5/95 
110.6 ± 10.3 
 
4.8 ± 4.3 (43.3) 
3.1 ±3.2 (32.3) 
6.8 ± 3.9 (38.6) 
14.6 ±10.0 
46.3 ±10.7 
 
1396.7 ± 1514.3 
7012.1 ± 3030.2 
 
9314.9 ± 2667.5 
34.7 ± 5.7 
40.2 ± 4.8 
16.4 ± 4.3 
43.4 ± 6.7 
 
42 
27 
45 
15 
13 
 
32.3 
15.0 
22.0 
 
23/77 
42.0 ± 8.5 
31.3 ± 3.8 
39.4 ± 7.2 
 
119.9 ± 12.7 
1.5 ± 0.4 
5.1 ± 0.9 
1.2 ± 1.3 
5.1 ± 0.6 
4/96 
99.9 ± 10.8 
 
4.0 ± 4.0 (34.8) 
2.6 ± 2.8 (25.9) 
6.5 ± 4.2 (37.2) 
13.1 ± 9.2 
46.4 ± 9.6 
 
1391.7± 1414.6 
7931.5 ± 3042.2 
 
8861.6 ± 2343.9 
34.6 ±5.0 
40.6 ± 4.8 
16.8 ± 4.6 
42.6 ± 7.4 
 
55 
24 
43 
20 
14 
 
3.6 
5.3 
14.2 
Data are expressed as mean + standard deviation or %, *proportion of high (including mild, 
moderate, severe and extremely severe) scores of depression ≥5, anxiety ≥4, and stress ≥8
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Table 2: Baseline demographic and lifestyle covariates assessed in the multivariate logistic regression model of presence of Mets of Illawarra (NSW, 
Australia) participants 
Category Baseline variable Univariate analysis Multivariate analysis 
    Coefficient Lower 95% CI Upper 95% CI P Odds Lower 95% CI Upper 95% CI P 
Demographic Age  0.14 0.01 0.02 <0.01 1.08 1.04 1.12 <0.01 
 
BMI  0.05 0.04 0.06 <0.01 1.26 1.18 1.36 <0.01 
 
Gender  -0.12 -0.23 -0.01 0.03 0.55 0.30 1.02 0.06 
  % Body Fat  0.01 0.01 0.02 <0.01 1.04 0.95 1.13 0.46 
Psychological DASS Depression  0.01 -<0.01 0.02 0.19 1.03 0.96 1.10 0.43 
 
DASS Anxiety  0.01 -0.01 0.03 0.21 
    
 
DASS Stress  <0.01 -0.01 0.02 0.57 
    
 
DASS Total  <0.01 -<0.01 0.01 0.23 
      SF-12 Mental  <0.01 -<0.01 0.01 0.82 
    Physical 
activity IPAQ  <0.01 <0.01 <0.01 0.64 
      Steps/day S1# -0.26 -0.48 -0.03 0.02 0.62 0.19 2.01 0.43 
 Steps/day S2# -0.27 -0.46 -0.07 0.01 0.61 0.22 1.66 0.33 
 Steps/day S3# -0.20 -0.37 -0.04 0.02 0.65 0.28 1.49 0.31 
 Steps/day S4# -0.25 -0.41 -0.10 <0.01 0.55 0.25 1.18 0.12 
Dietary Total Kilojoules  <0.01 <0.01 <0.01 0.12 1.00 1.00 1.00 0.23 
 
MUFA  -<0.01 -0.01 0.01 0.56 
    
 
PUFA  -<0.01 -0.02 0.01 0.46 
      Sat Fat  <0.01 -<0.01 0.01 0.39 
    Social Household Income C1@ -0.09 -0.24 0.06 0.24 
     Household Income C2@ -0.02 -0.14 0.10 0.75     
 
Education L1* -0.25 -0.91 0.42 0.47     
 
Education L2* -0.20 -0.86 0.46 0.56     
 
Education L3* -0.10 -0.77 0.56 0.76     
 
Education L4* -0.05 -0.74 0.64 0.89     
 
Education L5* -0.22 -0.90 0.46 0.53     
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  Education L6* -0.05 -0.73 0.63 0.89     
Gender uses male as the referent category. l#Steps/day S1 highly active, S2 active, S3 somewhat active, S4 low active. Steps per day are compared with sedentary as the 
referent category. @Household income category C1 >$160,000, C2 $80 - $159,999. Household income compared with <$80,000 as the referent category. *Education L1 
postgraduate degree, L2 university degree, L3 certificate/diploma, L4 trade/apprenticeship, L5 high school or leaving certificate, L6 school or intermediate certificate. 
Education levels are compared with no school certificate or other qualification as the referent category
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To examine CVD and CHD estimated risk, data were available for n=351 participants (Table 3). The 
median risk of experiencing cardiovascular disease within the next 10 years for all participants 
(interquartile range) was 3.89% (1.83 – 7.00). Most participants (88-92%) were in the low risk (<10%) 
category. Using linear regression, participants classified with MetS had a 4.50% increase in CVD risk 
compared to no-MetS participants (odds 4.50 (95% CI: 3.72, 5.28), p<0.01). Using logistic regression, 
it was identified that MetS participants were 8.1 times more likely to be at risk of CHD than others 
(odds 8.07 (95% CI: 3.16, 20.62), p<0.01).  
Table 3: Estimated 10 Year Cardiovascular Disease (CVD) Risk and Coronary Heart Disease (CHD) 
Risk (n=351) of Illawarra (NSW, Australia) participants 
Risk category CVD1 CHD2 
Low (<10%) 310 (88.3%) 324 (92.3%) 
Moderate (10 – 20%) 39 (11.1%) 26 (7.4%) 
High (>20%) 2 (0.6%) 1 (0.3%) 
1Based on published equation [6] 
2Based on published score sheets [7] 
 
A total of n=26 (6.9%) of participants were categorised as being insulin resistant (15 on prescribed 
hypoglycaemic medication, 11 with HbA1c>6%). Using logistic regression, MetS participants were 
found to be 12.7 times more likely to be insulin resistant (odds 12.73 (95% CI: 4.28, 37.85), p<0.01). 
In contrast, analysis of available data for MetS and ABI (n=372) found that MetS did not significantly 
predict peripheral artery disease (odds 0.91 (95% CI: 0.55, 1.51), p=0.72). 
Discussion 
Obesity is a public health problem that contributes significantly to the increasing prevalence of 
chronic diseases such as diabetes mellitus and CVD. However, given that metabolic risk may differ 
between obese individuals, the identification of those with MetS and the factors associated with this 
risk may assist in developing approaches to preventive services, especially since metabolic 
disturbances occur prior to the onset of chronic disease. These analyses provided some insights into 
who is at risk of having MetS and to what degree individuals with MetS increase their risk of 
developing chronic disease. The application of the harmonised equation proved useful in making this 
identification in an overweight clinical cohort that interestingly identified increased risk in 
developing CVD, CHD and insulin resistance but not PAD (as assessed using ABI). The latter may be 
due to the specificity of the measurement, and it was noted that most of the participants were at 
low risk of CVD. These results highlight the gaps between assessment of risk and the onset of 
disease, and this has implications for assessing outcomes for lifestyle intervention. While it is 
appropriate to identify at risk individuals and encourage lifestyle modification, a focus on behaviour 
changes and indications of reduced risk may be more appropriate than reduced disease incidence.  
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The importance of measuring MetS in individuals has not been confirmed, however as prevention 
programs aim to address individuals health issues before they develop into chronic disease, it may 
become a vital assessment tool. Interest in the metabolic syndrome was high between 1997 and 
2005, however since the most recent definition was published in 2009 [1], there appears to be a 
paucity of data utilising the harmonised definition. Our study included healthy participants aged 
between 25-54 years with a BMI in the range 24-40kg/m2. It is well documented that 
overweight/obesity is the most important precursor for development of MetS [19], so our 
participants represented those at greatest risk of MetS and at a point of greatest benefit from 
lifestyle change, the primary treatment option. This sub-analysis of the HealthTrack clinical trial at 
baseline demonstrated that amongst the many factors included in the analysis, only older age and 
higher BMI predicted the presence of MetS, as classified by the harmonised equation. As the 
development of MetS begins with excess central adiposity, the findings were not surprising, due to 
the prevalence of abdominal obesity in older overweight individuals [20]. Still, our analysis confirms 
the results of previous studies that have reported BMI and age to be associated with MetS [21] in 
large national surveys using the ATPIII criteria.  
Those classified as MetS in this cohort were associated with a higher percentage risk of developing 
CHD or CVD within the next ten years and of developing diabetes mellitus; however we were not 
able to predict peripheral artery disease, as indicated by ABI. The diagnosis of MetS is reported to 
increase the risk of CVD by 30-400%, with the variation likely due to differing definitions, populations 
studied, and length of follow-up [22-24]. In our cohort characterised by a low prevalence of 
moderate-high CVD risk (7-11%), those diagnosed with MetS had a 4.50% increase in CVD risk and 
were eight times more likely to develop CHD within the next 10 years compared to participants 
without MetS. A low ABI has previously been reported in participants with MetS [13]. We did not 
find an association between participants with MetS and low ABI, but our study only contained a 
small proportion of participants diagnosed with peripheral artery disease. 
Insulin resistance was strongly associated with MetS in our analyses, with a 12.7 times greater risk 
compared to individuals without MetS. This finding is similar to another study examining obese 
subjects with MetS that reported an adjusted relative risk of 10.3 for diabetes [25]. These findings 
are expected as insulin resistance is strongly and positively associated with BMI, most likely due to 
increased liver and visceral fat content and the associated inflammatory signalling [26]. 
We also examined other lifestyle factors. The effect of psychosocial stress on MetS appears to be 
reciprocal in that chronic stress induces MetS as well as the associated hormonal dysfunctions of 
MetS augment cortisol-induced stress [27]. More recently however, the GEA study indicated that 
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self-reported chronic stress did not predict MetS [28]. Our current analyses did not show any 
significant association between stress, anxiety, depression or quality of life and MetS. This may be 
due to the indirect methods used to assess mental health, which were similar to that used in the 
GEA study. In addition, Brunner et al [27] only demonstrated an association in male participants, 
whereas our study sample was predominantly female. 
From a broader social perspective, lower social position has been suggested as increasing the 
probability of MetS [11], as well as a low education level [29]. In contrast, our analyses found neither 
education level nor household income were significantly associated with MetS. The difference could 
be explained in terms of larger sample sizes (n= 8104 and 4341 respectively vs n=377), and different 
equations, but they also point to important differences in context. In the clinical decision making, 
education level and income may not be as relevant as they are for population health strategies. 
Physical activity is another important consideration. Low cardiorespiratory fitness has been 
suggested as a predictor of MetS in a large cohort with BMI 22-25 kg/m2 [12]. Our data did not 
confirm this finding which may be due to the greater BMI of our clinical cohort. From a dietary 
perspective, dietary fatty acids of vegetable origin may have a beneficial effect on the incidence of 
MetS [4]. In our analyses no significant association was found between dietary fatty acids and MetS, 
however the sample size was possibly too small to detect these associations given variations in food 
choices. 
The main limitation of our sub-study is that MetS and lifestyle factors were secondary outcome 
measurements and the sample size was not specifically powered for addressing the relationships 
considered here. Likewise, the HealthTrack population was generally healthy and middle-aged albeit 
overweight, and this differed to other studies investigating younger or older populations. However 
from a public health and primary healthcare perspective it is most important to identify MetS in its 
earlier stages, that is, when people are healthy and before they develop CVD or insulin resistance. 
One other limitation was the use of medication, other than those included in the calculation of 
MetS, CVD, CHD and insulin resistance; they were not adjusted for in the multivariate analysis. 
Conclusions 
This study examined the utility of the harmonised equation for assessment of MetS in a clinical 
cohort of healthy overweight/obese volunteers and confirmed that those at greatest risk are older, 
overweight individuals. Once MetS is identified it is important to implement multi-disciplinary 
lifestyle changes due to the strong correlation with cardiovascular disease and insulin resistance. The 
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classification of MetS will also be useful in determining the relative effects of lifestyle intervention 
over time. 
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